Scarica l'app Stockscreener
21.99
4.31%
-0.99
Evommune Inc Borsa (EVMN) Ultime notizie
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - The Chronicle-Journal
Leerink reiterates Evommune stock rating after conference chat - Investing.com Nigeria
RBC Capital initiates Evommune stock with outperform rating By Investing.com - Investing.com Canada
RBC Capital initiates Evommune stock with outperform rating - Investing.com India
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade - The Globe and Mail
Evommune initiated with an Outperform at RBC Capital - TipRanks
Evommune (NYSE:EVMN) Trading Down 6.7%Here's What Happened - MarketBeat
Evommune, Inc. (EVMN) Receives a Rating Update from a Top Analyst - The Globe and Mail
Evommune (NYSE:EVMN) Trading 6.9% HigherTime to Buy? - MarketBeat
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlight - PharmiWeb.com
Evommune Reports Q4 2025 Results and Pipeline Progress - TipRanks
Evommune reports Q4 EPS ($1.43), consensus (84c) - TipRanks
Evommune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - The Joplin Globe
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Evommune, Inc.: Lead in MRGPRX2 Modulation and Differentiated EVO756 Profile Support Buy Rating - TipRanks
EVMN Technical Analysis & Stock Price Forecast - Intellectia AI
Evommune (NYSE:EVMN) Trading Down 10.2%Time to Sell? - MarketBeat
Evommune (EVMN) Price Target Increased by 37.87% to 55.08 - Nasdaq
Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO Success - Yahoo Finance
What is the current Price Target and Forecast for Evommune Inc. (EVMN) - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Charles River Labs (CRL) - The Globe and Mail
Evommune (NYSE:EVMN) Trading Down 7.4%Time to Sell? - MarketBeat
Morgan Stanley Maintains Overweight on Evommune (EVMN) Feb 18 2026 - Meyka
Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch, analyses DelveInsight - openPR.com
Technical Analysis - Intellectia AI
Evommune Announces $125 Million Private Placement - The AI Journal
Evommune announces $125 million private placement - The Pharma Letter
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Finviz
Benzinga Stock Whisper Index Analysis - Intellectia AI
Evommune raises $125 million in private placement to fund R&D By Investing.com - Investing.com Canada
Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement - Yahoo Finance
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Evommune (NYSE:EVMN) Shares Gap UpHere's Why - MarketBeat
Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace - RTTNews
Evommune Inc on Feb 12, enters securities purchase agreement with investors - marketscreener.com
Evommune Announces $125 Million Private Placement Financing - TipRanks
Evommune Inc On Feb 12, Enters Securities Purchase Agreement With Investors - TradingView
Evommune Signs Multiple Material Agreements - TradingView
Evommune raises $125M privately - MSN
Evommune raises $125 million in private placement to fund R&D - Investing.com Australia
Evommune to Raise $125 Million Via Private Placement - marketscreener.com
Evommune's stock surges on strong results for new eczema drug - MSN
Evommune Secures $125M in Private Placement Agreement - Intellectia AI
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):